Atlas Trials

RC48-ADC Combinatioed Envolizumab in Locally Advanced or Metastatic Biliary Tract Cancer With Positive HER-2

Clinical trial NCT05417230 · UNKNOWN

Trial details

NCT number
NCT05417230
Sponsor
Jiangsu Cancer Institute & Hospital
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
Biliary Tract Cancer
Start date
2022-08-01
Primary completion
2024-08-01
Enrollment
29

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.